Recurrent B-Cell Non-Hodgkin Lymphoma (DBCOND0041834)

Identifiers

Synonyms

B-Cell Non-Hodgkin Lymphoma-Recurrent

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06209619	CC-99282 + Rituximab Early Post CART for Non-Hodgkin's Lymphoma	Golcadomide Rituximab	treatment	1	recruiting
NCT06618313	One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHL	No drug interventions	treatment	Not Available	not_yet_recruiting
NCT06395870	Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma	No drug interventions	treatment	1	recruiting
NCT04892277	CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies	Bendamustine Cyclophosphamide Fludarabine	treatment	1	recruiting
NCT05453396	Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies	Loncastuximab tesirine	treatment	2	recruiting
NCT04074746	Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas	AFM-13 Acimtamig Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT04578600	CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma	Azacitidine Lenalidomide Obinutuzumab	treatment	1	active_not_recruiting
NCT04659044	Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma	Hyaluronidase (human recombinant) Polatuzumab vedotin Rituximab Venetoclax	treatment	2	terminated
NCT05507541	TTI-622 in Combination with Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma	Maplirpacept Ontorpacept Pembrolizumab	treatment	2	recruiting
NCT05627245	Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment	Belinostat Tazemetostat	treatment	1	suspended
NCT01921387	Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies	Beta-D-Glucose Carmustine Cytarabine Etoposide Mechlorethamine	treatment	1 / 2	completed
NCT02628405	R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma	Beta-D-Glucose Carboplatin Cyclophosphamide Etoposide Ifosfamide Lenalidomide Rituximab	treatment	1 / 2	active_not_recruiting
NCT04635683	Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma	Lenalidomide Ublituximab Umbralisib	treatment	1	withdrawn
NCT00860171	Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	No drug interventions	treatment	1	terminated
NCT03103971	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia	Cyclophosphamide Fludarabine	treatment	1	terminated
NCT04995536	CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL	No drug interventions	treatment	1	withdrawn
NCT05801913	Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma	Modified vaccinia ankara	treatment	1	recruiting
NCT00764517	Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma	Cladribine Rituximab Vorinostat	treatment	2	completed
NCT05432635	Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma	Modified vaccinia ankara	treatment	1	recruiting
NCT01434472	High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma	Cyclosporine Fludarabine Mycophenolate mofetil Rituximab	treatment	2	terminated
NCT02992223	Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT	No drug interventions	Not Available	Not Available	completed
NCT05272384	Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma	Cedazuridine Decitabine Nivolumab	treatment	1	recruiting
NCT03147885	Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma	Escitalopram Selinexor	treatment	1 / 2	recruiting
NCT02483000	Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell Malignancies	Beta-D-Glucose Carmustine Cytarabine Etoposide Mechlorethamine	treatment	1	terminated
NCT01729806	Ipilimumab and Rituximab in Treating Patients With Relapsed or Refractory B-cell Lymphoma	Ipilimumab Rituximab	treatment	1	completed
NCT01695941	Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma	Alisertib Bortezomib Bortezomib D-mannitol Rituximab	treatment	1	active_not_recruiting
NCT04447716	An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment	Hyaluronidase (human recombinant) Lenalidomide Rituximab Venetoclax	treatment	1	recruiting
NCT03892525	Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma	Atezolizumab Selicrelumab	treatment	1	terminated
NCT02950220	Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Ibrutinib Pembrolizumab	treatment	1	completed
NCT02332980	Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas	Ibrutinib Idelalisib Pembrolizumab	treatment	2	completed
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT05936229	Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell Therapy	Interferon beta-1a Water	prevention	1 / 2	withdrawn
NCT03038672	Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas	Nivolumab Varlilumab	treatment	2	active_not_recruiting
NCT03003546	Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial	Paclitaxel Rituximab	treatment	1	completed
NCT01897012	Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas	Alisertib Romidepsin	treatment	1	completed
NCT02928510	Mechanisms of Idelalisib-Associated Diarrhea in Patients With Relapsed Chronic Lymphocytic Leukemia, Indolent Non-hodgkin Lymphoma, or Small Lymphocytic Lymphoma	Idelalisib	Not Available	Not Available	terminated
NCT04220008	Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma	Busulfan Clofarabine Cyclophosphamide Gemcitabine Mycophenolate mofetil Rituximab Tacrolimus Vorinostat	treatment	2	withdrawn